{"id":"https://openalex.org/W1570040135","doi":"https://doi.org/10.1111/j.1742-1241.2007.01335.x","title":"Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation","display_name":"Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation","alternate_titles":[],"publication_year":2007,"publication_date":"2007-03-22","ids":{"openalex":"https://openalex.org/W1570040135","doi":"https://doi.org/10.1111/j.1742-1241.2007.01335.x","mag":"1570040135","pmid":"https://pubmed.ncbi.nlm.nih.gov/17394446"},"language":"en","primary_location":{"id":"doi:10.1111/j.1742-1241.2007.01335.x","doi":"https://doi.org/10.1111/j.1742-1241.2007.01335.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1742-1241.2007.01335.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1742-1241.2007.01335.x","source":{"id":"https://openalex.org/S22344484","display_name":"International Journal of Clinical Practice","issn_l":"1368-5031","issn":["1368-5031","1742-1241"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Clinical Practice","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1570040135"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1742-1241.2007.01335.x","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5089955461","display_name":"Pierre\u2010Michel Llorca","orcid":"https://orcid.org/0000-0001-7438-8990","observed_orcids":["https://orcid.org/0000-0001-7438-8990"]},"institutions":[{"id":"https://openalex.org/I4210128870","display_name":"Centre Hospitalier Universitaire de Clermont-Ferrand","ror":"https://ror.org/02tcf7a68","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210128870"]}],"countries":["FR"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"P. M. Llorca","raw_affiliation_strings":["Service de Psychiatrie, Centre Hospitalier Universitaire, Clermont-Ferrand, France. pmllorca@chu-clermontferrand.fr","Service de Psychiatrie, Centre Hospitalier Universitaire, Clermont-Ferrand, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Service de Psychiatrie, Centre Hospitalier Universitaire, Clermont-Ferrand, France. pmllorca@chu-clermontferrand.fr","institution_ids":["https://openalex.org/I4210128870"]},{"raw_affiliation_string":"Service de Psychiatrie, Centre Hospitalier Universitaire, Clermont-Ferrand, France","institution_ids":["https://openalex.org/I4210128870"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5084507356","display_name":"Jos\u00e9\u2010Luis Fern\u00e1ndez","orcid":"https://orcid.org/0000-0002-4190-7341","observed_orcids":["https://orcid.org/0000-0002-4190-7341"]},"institutions":[{"id":"https://openalex.org/I909854389","display_name":"London School of Economics and Political Science","ror":"https://ror.org/0090zs177","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I909854389"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J.-L. Fernandez","raw_affiliation_strings":["London School of Economics, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"London School of Economics, London, UK","institution_ids":["https://openalex.org/I909854389"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5089955461"],"corresponding_institution_ids":["https://openalex.org/I4210128870"],"apc_list":{"value":2350,"currency":"USD","value_usd":2350},"apc_paid":null,"fwci":3.4192,"has_fulltext":true,"cited_by_count":47,"citation_normalized_percentile":{"value":0.90922684,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"61","issue":"4","first_page":"702","last_page":"710"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10272","display_name":"Mental Health Treatment and Access","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/escitalopram","display_name":"escitalopram","score":0.9679999947547913},{"id":"https://openalex.org/keywords/venlafaxine-extended-release","display_name":"venlafaxine extended release","score":0.9900000095367432},{"id":"https://openalex.org/keywords/major-depressive-disorder","display_name":"major depressive disorder","score":1.0},{"id":"https://openalex.org/keywords/selective-serotonin-reuptake-inhibitors","display_name":"selective serotonin reuptake inhibitors","score":0.9399999976158142},{"id":"https://openalex.org/keywords/serotonin-norepinephrine-reuptake-inhibitors","display_name":"serotonin-norepinephrine reuptake inhibitors","score":0.9129999876022339},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.75},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.8429999947547913},{"id":"https://openalex.org/keywords/antidepressant-efficacy","display_name":"antidepressant efficacy","score":0.5870000123977661},{"id":"https://openalex.org/keywords/head-to-head-comparison","display_name":"head-to-head comparison","score":0.5720000267028809},{"id":"https://openalex.org/keywords/economic-evaluation","display_name":"economic evaluation","score":0.6890000104904175}],"concepts":[{"id":"https://openalex.org/C2779583969","wikidata":"https://www.wikidata.org/wiki/Q423757","display_name":"Escitalopram","level":4,"score":0.9853893518447876},{"id":"https://openalex.org/C2776466888","wikidata":"https://www.wikidata.org/wiki/Q898407","display_name":"Venlafaxine","level":4,"score":0.9634124636650085},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8432241678237915},{"id":"https://openalex.org/C2780051608","wikidata":"https://www.wikidata.org/wiki/Q42844","display_name":"Major depressive disorder","level":3,"score":0.7301647663116455},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6805316209793091},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.5155796408653259},{"id":"https://openalex.org/C2909532165","wikidata":"https://www.wikidata.org/wiki/Q898407","display_name":"Venlafaxine Hydrochloride","level":5,"score":0.5073320269584656},{"id":"https://openalex.org/C2777490545","wikidata":"https://www.wikidata.org/wiki/Q409672","display_name":"Citalopram","level":4,"score":0.48896729946136475},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.4696974754333496},{"id":"https://openalex.org/C2777669559","wikidata":"https://www.wikidata.org/wiki/Q407617","display_name":"Sertraline","level":4,"score":0.437685489654541},{"id":"https://openalex.org/C31487548","wikidata":"https://www.wikidata.org/wiki/Q4859664","display_name":"Reuptake inhibitor","level":4,"score":0.41847527027130127},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3621530532836914},{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.1748391091823578},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.16601970791816711},{"id":"https://openalex.org/C2780733359","wikidata":"https://www.wikidata.org/wiki/Q331769","display_name":"Mood","level":2,"score":0.11536788940429688},{"id":"https://openalex.org/C558461103","wikidata":"https://www.wikidata.org/wiki/Q154430","display_name":"Anxiety","level":2,"score":0.06178298592567444}],"mesh":[{"descriptor_ui":"D000069470","descriptor_name":"Venlafaxine Hydrochloride","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003511","descriptor_name":"Cyclohexanols","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D003511","descriptor_name":"Cyclohexanols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003865","descriptor_name":"Major Depressive Disorder","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003865","descriptor_name":"Major Depressive Disorder","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015201","descriptor_name":"Meta-Analysis as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015283","descriptor_name":"Citalopram","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D015283","descriptor_name":"Citalopram","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017059","descriptor_name":"Models, Econometric","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D018687","descriptor_name":"Antidepressive Agents, Second-Generation","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D018687","descriptor_name":"Antidepressive Agents, Second-Generation","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1742-1241.2007.01335.x","doi":"https://doi.org/10.1111/j.1742-1241.2007.01335.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1742-1241.2007.01335.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1742-1241.2007.01335.x","source":{"id":"https://openalex.org/S22344484","display_name":"International Journal of Clinical Practice","issn_l":"1368-5031","issn":["1368-5031","1742-1241"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Clinical Practice","raw_type":"journal-article"},{"id":"pmid:17394446","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17394446","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International journal of clinical practice","raw_type":"Comparative Study"}],"best_oa_location":{"id":"doi:10.1111/j.1742-1241.2007.01335.x","doi":"https://doi.org/10.1111/j.1742-1241.2007.01335.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1742-1241.2007.01335.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1742-1241.2007.01335.x","source":{"id":"https://openalex.org/S22344484","display_name":"International Journal of Clinical Practice","issn_l":"1368-5031","issn":["1368-5031","1742-1241"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Clinical Practice","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320327235","display_name":"Servier","ror":"https://ror.org/034e7c066"},{"id":"https://openalex.org/F4320327918","display_name":"H. Lundbeck A/S","ror":"https://ror.org/0564cd633"},{"id":"https://openalex.org/F4320338413","display_name":"Cilag","ror":"https://ror.org/02fe4h741"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1570040135.pdf","grobid_xml":"https://content.openalex.org/works/W1570040135.grobid-xml"},"referenced_works_count":60,"referenced_works":["https://openalex.org/W72641942","https://openalex.org/W108869947","https://openalex.org/W126413145","https://openalex.org/W143336295","https://openalex.org/W189854980","https://openalex.org/W1539382539","https://openalex.org/W1545716081","https://openalex.org/W1867378313","https://openalex.org/W1965577946","https://openalex.org/W1967287253","https://openalex.org/W1970080702","https://openalex.org/W1975870015","https://openalex.org/W1985280182","https://openalex.org/W1987262076","https://openalex.org/W1989007151","https://openalex.org/W1994418303","https://openalex.org/W1994664270","https://openalex.org/W1996105921","https://openalex.org/W2017585287","https://openalex.org/W2018008180","https://openalex.org/W2019268145","https://openalex.org/W2029601342","https://openalex.org/W2035444856","https://openalex.org/W2036861336","https://openalex.org/W2037481801","https://openalex.org/W2052098936","https://openalex.org/W2058750823","https://openalex.org/W2060573155","https://openalex.org/W2062522126","https://openalex.org/W2067157495","https://openalex.org/W2067570300","https://openalex.org/W2068083208","https://openalex.org/W2070618004","https://openalex.org/W2073447934","https://openalex.org/W2083950600","https://openalex.org/W2089648538","https://openalex.org/W2099564543","https://openalex.org/W2104058480","https://openalex.org/W2112778345","https://openalex.org/W2113033541","https://openalex.org/W2114392292","https://openalex.org/W2114613490","https://openalex.org/W2114824785","https://openalex.org/W2115615534","https://openalex.org/W2122237296","https://openalex.org/W2128657027","https://openalex.org/W2130601017","https://openalex.org/W2131823335","https://openalex.org/W2140238215","https://openalex.org/W2146743061","https://openalex.org/W2155086372","https://openalex.org/W2198372611","https://openalex.org/W2319030879","https://openalex.org/W2473786944","https://openalex.org/W2504173400","https://openalex.org/W2994602737","https://openalex.org/W3177402257","https://openalex.org/W4249162025","https://openalex.org/W6607786286","https://openalex.org/W6667088598"],"related_works":["https://openalex.org/W2062522126","https://openalex.org/W1996554948","https://openalex.org/W1550290244","https://openalex.org/W2146033454","https://openalex.org/W1980215001","https://openalex.org/W2146659374","https://openalex.org/W4256255968","https://openalex.org/W2167820857","https://openalex.org/W125270029"],"abstract_inverted_index":{"Major":[0],"depressive":[1,45],"disorder":[2],"(MDD),":[3],"a":[4,13,65,146,164,178],"prevalent":[5],"and":[6,16,53,61,72,136,180,209],"serious":[7],"mental":[8],"illness,":[9],"is":[10,21,188,192,206],"associated":[11],"with":[12,43],"substantial":[14],"disease":[15],"economic":[17,55,143],"burden.":[18],"Long-term":[19],"pharmacotherapy":[20],"often":[22],"necessary;":[23],"selective":[24,67],"serotonin":[25,70],"reuptake":[26,32],"inhibitors":[27],"(SSRIs)":[28],"or":[29],"the":[30,36,58,73,155,172,201],"serotonin-noradrenaline":[31],"inhibitor":[33,68],"venlafaxine":[34,91,103,127,169,198],"are":[35,88,157],"most":[37],"frequently":[38],"prescribed":[39],"medications":[40],"in":[41,92,105,114,129,159,200],"patients":[42],"moderate-to-severe":[44],"symptoms.":[46,139],"This":[47],"article":[48],"reviews":[49],"head-to-head":[50],"clinical":[51],"studies":[52,156],"health":[54],"models":[56],"comparing":[57],"efficacy,":[59,95],"tolerability":[60,135],"cost-effectiveness":[62],"of":[63,69,77,94,131,142,154,174,203],"escitalopram,":[64],"dual-action":[66],"reuptake,":[71],"extended-release":[74],"(XR)":[75],"formulation":[76],"venlafaxine.":[78],"While":[79],"there":[80],"has":[81],"been":[82],"some":[83],"evidence":[84],"that":[85,161,190],"conventional":[86],"SSRIs":[87],"inferior":[89],"to":[90,133,168],"terms":[93,130],"escitalopram":[96,121,162,191],"was":[97],"at":[98,193],"least":[99,194],"as":[100,102,195,197],"effective":[101,196],"XR":[104,128,170,199],"reducing":[106],"Montgomery-Asberg":[107],"Depression":[108],"Rating":[109],"Scale":[110],"scores":[111],"from":[112,177],"baseline":[113],"two":[115],"short-term":[116],"(8-week)":[117],"comparative":[118],"studies.":[119],"Furthermore,":[120],"had":[122],"potentially":[123],"important":[124],"advantages":[125],"over":[126],"time":[132],"remission,":[134],"discontinuation":[137],"(withdrawal)":[138],"The":[140],"results":[141],"evaluations,":[144],"including":[145],"'gold":[147],"standard'":[148],"prospective":[149],"study":[150],"conducted":[151],"alongside":[152],"one":[153],"consistent":[158],"suggesting":[160],"offers":[163],"more":[165],"cost-effective":[166],"alternative":[167],"for":[171],"treatment":[173,202],"MDD,":[175,204],"both":[176],"healthcare":[179],"societal":[181],"perspective.":[182],"Based":[183],"on":[184],"this":[185],"evidence,":[186],"it":[187],"concluded":[189],"but":[205],"better":[207],"tolerated":[208],"may":[210],"also":[211],"have":[212],"cost":[213],"advantages.":[214]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1570040135","counts_by_year":[{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-17T12:49:18.490984","created_date":"2016-06-24T00:00:00"}
